Head-to-Head

Creative Medical Technology Holdings, Inc. Common Stock vs. Halozyme Therapeutics, Inc.

CELZ

Creative Medical Technology Holdings, Inc. Common Stock

$1.22 -1.61%

VS HALO

Halozyme Therapeutics, Inc.

$98.66 -2.00%

Creative Medical Technology Holdings, Inc. Common Stock and Halozyme Therapeutics, Inc. are evenly matched on the factors we track — the better pick depends on what you're optimizing for.

Size & Scale

CELZHALO
Market Cap $8.04 million $11.20 billion
Revenue (TTM) $1.66 billion
Net Income (TTM) $413.60 million

HALO leads on 1 of 1 size & scale factors.

Valuation

CELZHALO
P/E Ratio 28.85
Price / Book 78.01
Price / Sales 6.73

CELZ and HALO split the valuation factors evenly.

Profitability

CELZHALO
Net Margin 24.86%
Return on Equity 288.13%

CELZ and HALO split the profitability factors evenly.

Risk & Sentiment

CELZHALO
Short Interest 0.25% 9.79%

CELZ leads on 1 of 1 risk & sentiment factors.

Dig deeper: CELZ overview, CELZ financials, HALO overview, HALO financials.

Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.